Dyne Therapeutics, Inc（DYN）の財務DYNDyne Therapeutics, Inc

Evaluating the bottom line, Dyne Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -81.57%, provide a clear picture of how effectively DYN converts its operational activities into shareholder value.

In the context of the broader market, DYN competes directly with industry leaders such as RCUS and DNLI. With a market capitalization of $2.88B, it holds a significant position in the sector. When comparing efficiency, DYN's gross margin of N/A stands against RCUS's 100.00% and DNLI's 76.61%. Such benchmarking helps identify whether Dyne Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Dyne Therapeutics has been experiencing significant net income losses, with Q2 2026 reporting a loss of $178,556,000. The forward P/E ratio is currently at 0, indicating no earnings expectations in the near term. The company's current ratio remains strong at 12.02, suggesting good short-term financial health despite ongoing losses.